Compugen will sponsor the ongoing two-part Phase 1 trial, which includes the evaluation of the combination of COM701 and Opdivo in four tumor types, including non-small cell lung, ovarian, breast, and endometrial cancer.
Contributed Author:
Bristol-Myers Squibb Company and Compugen